On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary, HTA Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to initiate clinical trials for their Class 1 innovative drug, [18F] Piramide Injection.
[18F] Piramide: A PET Imaging Agent for Enhanced Melanoma Detection
[18F] Piramide Injection is a positron emission tomography (PET) imaging agent that rapidly binds with melanoma within the body, exhibiting good specificity and high sensitivity. This advancement significantly improves the accuracy of melanoma diagnosis and staging, providing precise guidance for clinical treatment decisions. The development of this agent is set to enhance the precision of melanoma detection and management.
Patent Acquisition and Clinical Trial Significance
HTA Co., Ltd. acquired the patent for [18F] Piramide compound in December 2022 from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The approval to proceed with clinical trials by the NMPA marks a significant milestone in the development of this innovative diagnostic tool, which could lead to better patient outcomes and more targeted treatment strategies for melanoma.-Fineline Info & Tech
